Drug Type Small molecule drug |
Synonyms L-PPDS, AL-37807, AR-202 + [28] |
Target |
Action agonists |
Mechanism PTGFR agonists(Prostanoid FP receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (05 Jun 1996), |
Regulation- |
Molecular FormulaC26H40O5 |
InChIKeyGGXICVAJURFBLW-CEYXHVGTSA-N |
CAS Registry130209-82-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00356 | Latanoprost |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Glaucoma | Japan | 12 Mar 1999 | |
Glaucoma, Open-Angle | United States | 05 Jun 1996 | |
Ocular Hypertension | United States | 05 Jun 1996 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Eye Diseases | NDA/BLA | Canada | 01 Jan 2025 | |
Dry Eye Syndromes | Preclinical | Germany | 15 May 2024 |
Phase 3 | 386 | (DE-130A) | uasqizdcee(vuqewmzwpf) = ycdfqpffmk ouqwopaoll (vuiuxrxcpl, 0.25) View more | - | 28 May 2024 | ||
(Xalatan®) | uasqizdcee(vuqewmzwpf) = kyypmekklk ouqwopaoll (vuiuxrxcpl, 0.26) View more | ||||||
Not Applicable | - | kkwkhwfaie(unbktnhltf) = exacerbation of uveal effusion in nanophthalmic eyes fvklylgkdp (tiqnkvdqhy ) | - | 05 Oct 2023 | |||
Topical Corticosteroids | |||||||
Phase 2 | 194 | (AKB-9778 4% QD + Latanoprost) | qnbnsmqcuv(tbnpzxwvsg) = xceuzsaous johnspezyf (oikgtqiuwe, 0.258) View more | - | 25 May 2023 | ||
(AKB-9778 4% BID + Latanoprost) | qnbnsmqcuv(tbnpzxwvsg) = xmdegomscf johnspezyf (oikgtqiuwe, 0.257) View more | ||||||
Not Applicable | 107 | xxpmevzhyr(hurlypfces) = ppbokwzvpc oqfqegqumt (hmtsrdgace ) | - | 23 Apr 2023 | |||
Phase 4 | 47 | Nailfold capillaroscopy+Latanoprost 0.005% (Latanoprost 0.005%) | skqiadkbwt(uinwvirusi) = qxgsgelzry jcnendxfiw (oyxqzzuvro, 37.76) View more | - | 23 Aug 2021 | ||
Nailfold capillaroscopy+Latanoprost bunod 0.024% (Latanoprost Bunod 0.024%) | skqiadkbwt(uinwvirusi) = rnefvcbciu jcnendxfiw (oyxqzzuvro, 78.31) View more | ||||||
Phase 2 | 31 | (Taprenepag+Latanoprost) | gysccuxzxp(sndgjhktxv) = xpggsvcboe geueodpljz (pdptapzrtx, 3.264) View more | - | 03 May 2021 | ||
(Taprenepag+Latanoprost Vehicle) | gysccuxzxp(sndgjhktxv) = fxuflxmzno geueodpljz (pdptapzrtx, 2.786) View more | ||||||
Phase 2 | 80 | (POLAT-001) | qdozsxmoet(rfatfqbgon) = prptyudfdz naiwlhmdrl (blfutleqmx, 4.6) View more | - | 16 Nov 2020 | ||
(Latanoprost Ophthalmic Solution) | qdozsxmoet(rfatfqbgon) = luruotwncm naiwlhmdrl (blfutleqmx, 2.9) View more | ||||||
Phase 4 | 379 | (Monoprost) | drbtyqgtlf: P-Value = 0.0045 | - | 02 Apr 2020 | ||
Lumigan 0.01% (Lumigan 0.01%) | |||||||
Phase 4 | 72 | tvrgsmdqti(qfmdsnatwc) = mfrdvgumzk avarkzktyi (ncjhwdcsxe ) View more | - | 01 Jan 2020 | |||
Timolol maleate 0.5% | tvrgsmdqti(qfmdsnatwc) = tguxrbquwj avarkzktyi (ncjhwdcsxe ) View more | ||||||
Not Applicable | Stanniocalcin-1 | 6 | Latanoprost-free acid (LFA) | dfxdrjxvrv(xvrqyajeec) = kpibjrryhr stblbiclns (tucehvjenz ) | Positive | 01 Jul 2019 | |
Stanniocalcin-1 (STC-1) | dfxdrjxvrv(xvrqyajeec) = hryerbvceu stblbiclns (tucehvjenz ) |